Navigation Links
Advanced targeted therapies effective as first-line treatment for lung cancer
Date:8/1/2009

/p>

Erlotinib targets a protein called the epidermal growth factor receptor (EGFR). EGFR, which helps cells divide, is found at abnormally high levels on the surface of many types of cancer cells, including many cases of NSCLC.

The study enrolled 1,949 patients, and 889 of which did not have progressive disease following four cycles of chemotherapy and were randomized to 150 mg/day of erlotinib or placebo. Patients who received erlotinib experienced significantly prolonged progression-free survival (PFS) over those on placebo a 29 to 31 percent reduction in risk of progression with erlotinib or an increase of progression-free survival time of 41 to 45 percent. The disease control rate (including patients whose tumors disappeared or reduced in size or did not get larger) was 40.8 percent with erlotinib versus 27.4 percent with placebo. The study also met a key secondary endpoint of extending overall survival in patients who received erlotinib immediately after initial chemotherapy. A statistically significant improvement in overall survival was seen in this pre-planned final analysis of the total patient population.

Further, a PFS benefit was seen with erlotinib regardless of the patient's gender, smoking history, ethnicity, or whether testing indicated the patient's tumor expressed the EGFR.

"The results of this study broaden the patient population for whom erlotinib can be effective," said Federico Cappuzzo, M.D., lead author and professor and vice director of the Department of Medical Oncology at Instituto Clinico Humanitas in Milan, Italy. "Given that lung cancer is the leading cause of cancer deaths worldwide and that NSCLC is the most common and deadly form of lung cancer, the PFS time that erlotinib can offer represents a significant advance in treatment of this disease."

Dr. Cappuzzo will present this study on Saturday, August 1 at 2:30 pm PT in Moscone West, Room 2001-2005, Level 2.

MOLECULAR MARKERS AND
'/>"/>

Contact: Liz Wulderk
lwulderk@spectrumscience.com
443-506-1931
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Smith & Nephew Highlights Advanced Wound Management Progress
2. Patient safety advanced by revised heparin standards
3. AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
4. Penile Prosthesis Surgery Infection Rates Reduced With The No-Touch Technique By Dr. J. Francois Eid of Advanced Urological Care
5. Leading Independent Analyst Firm States Silver Creek Systems Holds A Virtual Monopoly In Delivering Advanced Product Data Quality Capabilities
6. Surgery remans an option for advanced lung cancer
7. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
8. Hendrick Health System Deploys Sentillions Tap & Go Advanced Authentication Solution
9. Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer
10. Marienkrankenhaus Hamburg Installs Visage(R) CS Enterprise Wide Advanced Visualization Solutions
11. Advanced Bag Design for Cryopreservation: The New CryoMACS(R) Freezing Bag
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... has released a new blog post explaining how to find ... SUVs are large vehicles that fare well in crash tests. ... regular car shows that passengers from the first car have ... crashes, but these large vehicles may be unstable and they ... now possible to find low cost car insurance plans on ...
(Date:4/21/2015)... Carinsurancehints.com has released a new blog ... impact on auto insurance prices . , ... prices. Clients should review their insurance options before deciding ... under several forms. Some of the popular policies provide ... compare online rates and find the best prices in ...
(Date:4/21/2015)... April 21, 2015 Respected academic institution ... strategy , Visage Imaging Inc. (“Visage”), a wholly ... has signed a seven-year contract with University of Florida ... Florida. The deal furthers the penetration of ... a key area of the North American enterprise imaging ...
(Date:4/21/2015)... Now in its fifteenth year, ... to unite over 3,000 senior attendees from across ... Suburban Collection Showplace on June 3 and 4. ... Ford, and Kia are set to deliver headline ... is reshaping automotive as connectivity paves the way ...
(Date:4/21/2015)... According to a recent article published by ... made naloxone available for anyone to have access to. ... without a doctor’s order- in an attempt to reduce ... state police will also begin carrying naloxone on hand. ... an opiate overdose reversal medication. The medicine helps relieve ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes For SUVs Are Available Online 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 2Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 3Health News:Drug Rehab Philadelphia Comments on Gov. Wolf’s Decision to Make Naloxone Widely Available 2
... can have a significantly beneficial effect in patients with ... randomize emphysema patients to receive either LVRS or non-surgical ... good treatment alternative for selected emphysema patients since it ... of life for a period of at least five ...
... , , SAN FRANCISCO, July ... gay, lesbian, bisexual, and transgender civil rights organization, today announced ... on Saturday, July 25, 2009, at the Westin St. Francis ... Progress," speakers will discuss issues impacting the LGBT community,s strive ...
... EATONTOWN, N.J., July 23 Osteotech, Inc. (Nasdaq: ... of biologic products for regenerative healing, announced today that the ... be released Wednesday, July 29, 2009. The management team of ... July 30, 2009, at 10:00 a.m. (EDT) to discuss the ...
... , , , , ... , , SAN DIEGO, July 23 /PRNewswire-FirstCall/ ... focused on developing products for minimally disruptive surgical treatments for the spine, announced today ... NuVasive reported second quarter revenue of $88.5 million, a 54.1% increase over ...
... , , WASHINGTON, July 23 ... that advocates for cancer patients and community providers of cancer care, ... saying: , , "We strongly ... on what works and fix what is broken., Unfortunately, that is ...
... MOUNTAIN VIEW, Calif., July 23 Omnicell, Inc. (Nasdaq: ... announced results for its second quarter ended June 30, 2009. , ... of 2009 was $52.6 million, up $0.4 million or 0.8% from the first ... of 2008. , , Second quarter ...
Cached Medicine News:Health News:Lung volume reduction surgery shown to prolong and improve life for some emphysema patients 2Health News:Human Rights Campaign Announces Speakers at 25th Annual Bay Area Gala 2Health News:Human Rights Campaign Announces Speakers at 25th Annual Bay Area Gala 3Health News:Osteotech Announces Second Quarter 2009 Financial Results Release and Conference Call 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 3Health News:NuVasive Reports Second Quarter 2009 Financial Results 4Health News:NuVasive Reports Second Quarter 2009 Financial Results 5Health News:NuVasive Reports Second Quarter 2009 Financial Results 6Health News:NuVasive Reports Second Quarter 2009 Financial Results 7Health News:NuVasive Reports Second Quarter 2009 Financial Results 8Health News:NuVasive Reports Second Quarter 2009 Financial Results 9Health News:NuVasive Reports Second Quarter 2009 Financial Results 10Health News:NuVasive Reports Second Quarter 2009 Financial Results 11Health News:NuVasive Reports Second Quarter 2009 Financial Results 12Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 2Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 3Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 4Health News:Omnicell Announces Second Quarter 2009 Results 2Health News:Omnicell Announces Second Quarter 2009 Results 3Health News:Omnicell Announces Second Quarter 2009 Results 4Health News:Omnicell Announces Second Quarter 2009 Results 5Health News:Omnicell Announces Second Quarter 2009 Results 6Health News:Omnicell Announces Second Quarter 2009 Results 7Health News:Omnicell Announces Second Quarter 2009 Results 8Health News:Omnicell Announces Second Quarter 2009 Results 9Health News:Omnicell Announces Second Quarter 2009 Results 10Health News:Omnicell Announces Second Quarter 2009 Results 11Health News:Omnicell Announces Second Quarter 2009 Results 12
(Date:4/21/2015)... , April 21, 2015 The North ... at a CAGR of 7.9% from 2014 to 2019. ... ) command larger shares in the dermatology diagnostic ... to grow at the highest CAGR of 9.8% during ... devices market is driven by factors such as rising ...
(Date:4/21/2015)... This report analyzes the worldwide markets for ... Equipment for Therapeutic Apheresis, and Equipment for Donor Apheresis. ... Plasmapheresis, Plateletpheresis, and Others. The report provides separate comprehensive ... Japan , Europe ... World. Annual estimates and forecasts are provided for the ...
(Date:4/21/2015)... According to a new ... Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, ... Residual Contamination, Adventitious Agents) - Global Forecast to ... Testing Market was valued at $1,758.69 Million in ... a CAGR of 12.23% to reach $3,130.85 Million ...
Breaking Medicine Technology:North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 2North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 3World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4
... Sept. 14 ThermoGenesis Corp. (Nasdaq: KOOLD ), ... and store adult stem cells, said today that revenues for ... revenues of $4.0 million for the same quarter a year ... $4.8 million. The Company recorded disposable revenues of ...
... WALTHAM, Mass., Sept. 14, 2010 Amylin Pharmaceuticals, Inc. ... (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ... research findings on BYETTA® (exenatide) injection and the investigational ... presented at the 46th Annual Meeting of the European ...
Cached Medicine Technology:ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 2ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 3ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 4ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 5ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 6ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 7BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 2BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 3BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 5BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 6BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 7
For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
... tips. Each box contains 1000 tips (5 bags ... tips (4 bags of 50 tips). Also available ... per pack. Bulk Packs are sealed with a ... quick access to Gilsons Diamond Tips. Bulk Packs ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels - Ideal for use with CastAway System...
Medicine Products: